Form 4: ClearPoint Neuro Director Sells Shares to Cover Tax Liability from RSU Vesting

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., sold 10,000 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Timothy T. Richards, a Director of ClearPoint Neuro, Inc. (CLPT), reported the sale of 10,000 shares of common stock.
• The transaction occurred on June 10, 2025, at a weighted average sales price of $13.28 per share, with individual sales prices ranging from $13.27 to $13.31.
• The sale was made specifically to cover the tax liability incurred from the vesting of 21,903 restricted stock units on May 16, 2025, which were originally granted on May 16, 2024.
• Following this transaction, Mr. Richards beneficially owns 77,381 shares of ClearPoint Neuro common stock.

Sentiment

Score: 5

Explanation: The transaction is neutral as it is a non-discretionary sale to cover tax liabilities from vested equity, rather than a discretionary sale based on a change in outlook. The director retains a substantial holding.

Positives

• The sale was for a specific, non-discretionary purpose (tax liability), indicating it was not a discretionary sale based on a negative outlook for the company.
• The director retains a significant holding of 77,381 shares, demonstrating continued alignment with shareholder interests.

Negatives

• A director selling shares, even for tax purposes, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common for executives and directors receiving equity compensation. It does not provide broader insights into ClearPoint Neuro's industry position or market trends.

Stakeholder Impact

• Shareholders: The sale slightly reduces the director's direct ownership, but the reason (tax liability) suggests no negative sentiment towards the company's future, thus the impact is likely minimal.

Key Dates

Recommendation

Keywords

ClearPoint Neuro, CLPT, Timothy T. Richards, Director, SEC Form 4, Insider Trading, Stock Sale, Tax Liability, Restricted Stock Units, Equity Compensation